Aligos Therapeutics (NASDAQ:ALGS) Rating Increased to Strong-Buy at Cantor Fitzgerald

Posted by Stanley Muller on May 22nd, 2026

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) was upgraded by research analysts at Cantor Fitzgerald to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

ALGS has been the subject of several other reports. Westpark Capital started coverage on Aligos Therapeutics in a research report on Thursday, March 26th. They issued a “buy” rating and a $48.00 price objective for the company. Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $37.20.

Check Out Our Latest Stock Analysis on ALGS

Aligos Therapeutics Price Performance

Shares of ALGS stock opened at $5.71 on Thursday. The company has a market capitalization of $35.34 million, a PE ratio of -0.66 and a beta of 2.28. The firm’s 50-day moving average is $6.91 and its two-hundred day moving average is $7.92. Aligos Therapeutics has a 12 month low of $5.12 and a 12 month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.29) by $0.08. The business had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $0.25 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. Sell-side analysts forecast that Aligos Therapeutics will post -7.54 EPS for the current year.

Institutional Trading of Aligos Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Aligos Therapeutics by 22.8% during the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after buying an additional 31,913 shares during the period. SummitTX Capital L.P. acquired a new stake in shares of Aligos Therapeutics in the fourth quarter valued at $1,299,000. Verition Fund Management LLC purchased a new stake in shares of Aligos Therapeutics in the 4th quarter valued at $664,000. LPL Financial LLC lifted its stake in Aligos Therapeutics by 19.7% during the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after acquiring an additional 10,880 shares in the last quarter. Finally, DRW Securities LLC acquired a new position in Aligos Therapeutics during the 4th quarter worth about $111,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

(Get Free Report)

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.